Ledaga (Chlormethine)

Chlormethine is an alkylating agent that covalently binds to DNA, forming cross‑links that block replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting the rapidly dividing malignant T‑cells present in the skin.

The dosage of Ledaga is determined by the prescribing clinician based on the extent and stage of skin involvement. Typically, a thin layer of the 0.016% gel is applied once daily to the affected area, but exact instructions are individualized.

Safety of chlormethine during pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the product should be avoided unless the potential benefit justifies the potential risk to the fetus or infant.

Enquiries for Ledaga can be submitted on the product page at gnhindia.com. Provide the required quantity, and GNH India will verify institutional or trade credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative to Ledaga is other topical alkylating agents such as mechlorethamine or phototherapy options. Compared with systemic therapies, Ledaga offers localized treatment with fewer systemic effects, but local skin irritation is more common. Choice depends on disease stage, prior treatments, and patient tolerance.

Ledaga should be stored at room temperature, below 25 °C, in its original container. Protect the gel from direct light and moisture. Keep the product out of reach of children and avoid freezing. Use a clean fingertip or applicator to prevent contamination.

Ledaga is applied topically to the skin lesions. The prescriber advises a thin, even layer to be spread over the affected area, usually once daily. Hands should be washed before and after application, and the treated skin should be covered only if directed by the clinician.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, and deep ulceration or necrosis of the skin at the application site. Patients should be instructed to seek immediate medical attention if they notice extensive blistering, swelling, or systemic symptoms.

Ledaga should not be used on patients with known hypersensitivity to chlormethine or other nitrogen‑mustard compounds, on open wounds, mucous membranes, or infected skin lesions. It is also contraindicated in individuals where the risks of pregnancy or breastfeeding outweigh potential benefits.